We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
CIRS

FUJIREBIO

  Gold Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fujirebio’s Spinal-Tap Test for Alzheimer’s Disease Could Eliminate Need for PET Scans

By MedImaging International staff writers
Posted on 06 May 2022
Print article
Image: Lumipulse G β-Amyloid Ratio (1-42/1-40) (Photo courtesy of Fujirebio Diagnostics)
Image: Lumipulse G β-Amyloid Ratio (1-42/1-40) (Photo courtesy of Fujirebio Diagnostics)

Alzheimer’s disease (AD) is a leading cause of disability and death, but current diagnostic methods are limited. AD develops over many years, long before symptoms are evident, but the lack of accessible diagnostics results in many patients remaining undiagnosed until the disease is well advanced, when few effective interventions remain. A key feature of AD is the presence of β-Amyloid plaques in the brain. β-Amyloid plaques are believed to contribute to the loss of cognitive function that characterizes AD, but accurately evaluating amyloid pathology has been difficult. Clinicians have relied primarily on cognitive assessments, including standardized cognitive screening tests. However, in early stages of the disease, a diagnosis of AD relying primarily on cognitive tests has been shown to be incorrect in approximately 50-60% of patients. Now, a new in vitro diagnostic (IVD) test for the assessment of β-Amyloid pathology in patients being evaluated for AD offers an alternative to the current standard for determining amyloid-pathology, amyloid positron emission tomography (PET) brain imaging which is expensive, subjective and time consuming.

The Lumipulse G β-Amyloid Ratio (1-42/1-40) test from Fujirebio Diagnostics, Inc. (Malvern, PA, USA) is an accurate, minimally invasive, accessible measure of β-Amyloid that can detect the formation of amyloid plaques early in the disease. It is intended for use in adult patients aged 55 years and older presenting with cognitive impairment who are being evaluated for Alzheimer’s disease and other causes of cognitive decline. The β-Amyloid Ratio test measures the concentrations of β-Amyloid 1-42 and β-Amyloid 1-40 in the CSF to calculate a numerical ratio as a proxy for the presence of β-Amyloid plaque in the brain.

Fujirebio has been granted De Novo marketing authorization by the U.S. Food and Drug Administration (FDA) for the company’s Lumipulse G β-Amyloid Ratio (1-42/1-40) IVD test for the assessment of β-Amyloid pathology in patients being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. The test, which was granted Breakthrough Device Designation by the FDA, is the first FDA-authorized in vitro diagnostic test in the U.S. to aid in the assessment of Alzheimer’s disease and other causes of cognitive decline.

“FDA authorization of the Lumipulse G β-Amyloid Ratio (1-42/1-40) test and the upcoming U.S. launch are important milestones in the campaign to transform AD into a manageable disease,” said Monte Wiltse, President and CEO at Fujirebio Diagnostics, Inc. “Patients, physicians and families now have a valuable new tool to help identify those individuals whose early symptoms may be indicative of AD, providing the opportunity to adopt life style changes and potentially to access new therapies aimed at slowing or stopping disease progression. FDA authorization of this first IVD biomarker test reflects our ongoing commitment to working with the healthcare community and AD advocates to achieve significant progress against this devastating disease.”

“The development of accurate tests for AD using biomarkers found in the CSF or other bodily fluids is a requirement if we are to make real progress against this dreaded disease,” added William Hu, MD, PhD is Chief, Division of Cognitive Neurology at Robert Wood Johnson Medical School and Principal Investigator of the Hu Lab, which focuses on researching fluid biomarkers for AD and other neurodegenerative disorders. “The importance of early diagnosis in AD is widely acknowledged, but until now, there has been no approved biomarker test available to clinicians and patients. FDA authorization of the Fujirebio β-Amyloid Ratio test is a significant advance that marks the advent of a new era, facilitating more efficient clinical trials for new AD therapies and enabling patients and their doctors to make more informed decisions and take action much earlier in the disease process.”

Related Links:
Fujirebio Diagnostics, Inc. 


Print article
Radcal
Sun Nuclear

Channels

Radiography

view channel
Image: CE-marked and FDA-cleared ExacTrac Dynamic enables the delivery of precision radiotherapy (Photo courtesy of Brainlab)

Next-Gen Technology Enables Precision Radiotherapy with “On-The-Fly” X-Ray Confirmation

Deep Inspiration Breath Hold (DIBH) is a well-established technique and standard of care in treating breast cancer with radiation therapy. When a patient takes a deep breath, the distance between the heart... Read more

MRI

view channel
Image: fMRI can be used as non-invasive method for predicting complications in chronic liver disease (Photo courtesy of Pexels)

Functional MRI (fMRI) Offers Non-Invasive Method for Risk Assessment in Liver Disease

In a recent study, a team of scientists has shown that functional magnetic resonance imaging (fMRI) can be used as a non-invasive method for predicting complications in chronic liver disease.... Read more

Ultrasound

view channel
Image: Resona I9 ultrasound system features innovative design elements (Photo courtesy of Mindray)

Mindray’s Latest Resona I9 Ultrasound System Provides Innovation-Driven Experience

Mindray (Shenzhen, China) has launched a new ultrasound system which provides an entirely new experience, driven by innovation to address today’s clinical challenges. Mindray’s latest Resona I9 ultrasound... Read more

Imaging IT

view channel
Illustration

Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology

The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more

Industry News

view channel
Image: Global diagnostic imaging market is driven by technological advancements (Photo courtesy of Pexels)

Global Diagnostic Imaging Market to Surpass USD 33 Billion by 2026

The global diagnostic imaging market is one of the most critical segments of the healthcare sector. Medical imaging helps in early detection and diagnosis of diseases at a stage when they can be easily... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.